13FGuru
Sign in with Google Sign in with Discord

NASDAQ · Health Care

Alnylam Pharmaceuticals ALNY

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1.

Sources StockAnalysis company profile stockanalysis.com
Biotechnology: Pharmaceutical Preparations

Company profile

Business mix

  • The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria.
  • It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis.
  • In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis.
  • Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management.

Current key questions

  • Can the company's products, services, or pipeline expand adoption within biotechnology?
  • How do reimbursement, regulation, clinical data, patents, and commercial execution affect growth?
  • Can margins and cash flow improve while funding research, manufacturing, or go-to-market investment?
Holders 2 Current sample portfolio
Public mentions 0 Videos / interviews / letters
Valuation snapshot
PE 76.72 FCF 1.59% Buyback -6.45%
2026-06-07

Current firm holders

Firm Weight Value Filing period
Baillie Gifford legacy James Anderson 0.8% $825.1M 2026-03-31
Bridgewater Associates Ray Dalio 0.2% $35.3M 2026-03-31

Recent trading changes over the last 2 quarters

Last 1 quarters Last 2 quarters Last 3 quarters Last 4 quarters
Net buyers 1 Last 2 13F filing periods
Net reducers 1 Last 2 13F filing periods
Unchanged holders 1 Share count unchanged
Increase amount $24.0M Estimated from net added shares
Reduction amount $97.8M Estimated from net reduced shares
Net share change / base shares -7.9% -222,809 / 2,823,267
Bridgewater Associates Ray Dalio 2 filing periods
13F 2025-12-31 Filed 2026-02-13
Major increase Shares 152.5% 13F value change +$18.6M
13F 2026-03-31 Filed 2026-05-15
Major increase Shares 24.5% 13F value change +$1.2M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 33,911 Last 2 periods +72,681 (+214.3%) Total shares 106,592 Value $35.3M
Baillie Gifford legacy James Anderson 2 filing periods
13F 2025-12-31 Filed 2026-01-23
Minor reduction Shares -6.8% 13F value change -$237.7M
13F 2026-03-31 Filed 2026-05-08
Minor reduction Shares -4.1% 13F value change -$209.1M
Settlement As of 13F 2026-03-31 · Filed 2026-05-08
Base shares 2,789,356 Last 2 periods -295,490 (-10.6%) Total shares 2,493,866 Value $825.1M
Soros Fund Management George Soros 2 filing periods
13F 2025-03-31 Filed 2025-05-15
New Shares - 13F value change +$16.2M
13F 2025-06-30 Filed 2025-08-14
Sold out Shares -100.0% 13F value change -$16.2M
Settlement As of 13F 2025-06-30 · Filed 2025-08-14
Base shares 0 Last 2 periods +0 (New) Total shares 0 Value $0

Recent mentions

No public mentions.